Table 2 SNPs correlate with severity of TIPN†(grade 0–1 vs. grade 2–3) in all patients and in breast cancer patients (subset analysis), and SNPs correlate with TIPNa (grade 0–1 vs. grade 2–3) at 1 year after completion of taxane treatment in all patients
Gene | SNP | Odds ratio | Odds ratio (95% C.I. b) | P-value |
|---|---|---|---|---|
SCN9A | rs7607967 | 1.749 | 0.889–3.441 | 0.1054 |
rs12994338 | 0.952 | 0.492–1.841 | 0.8836 | |
rs13017637 | 3.463 | 1.456–8.237 | 0.0050 | |
SCN10A | rs12632942 | 1.024 | 0.498–8.237 | 0.9491 |
rs6795970 | 0.949 | 0.450–1.998 | 0.8894 | |
A subset analysis in Breast only | ||||
SCN9A | rs7607967 | 1.822 | 0.864–3.842 | 0.1151 |
rs12994338 | 0.913 | 0.442–1.888 | 0.8061 | |
rs13017637 | 5.053 | 1.743–14.641 | 0.0029 | |
SCN10A | rs12632942 | 1.262 | 0.569–2.802 | 0.567 |
rs6795970 | 1.135 | 0.515–2.501 | 0.7537 | |
Analysis at 1 year after completion of taxane treatment in all patients | ||||
SCN9A | rs7607967 | 0.735 | 0.313–1.728 | 0.4805 |
rs12994338 | 0.952 | 0.418–2.167 | 0.9069 | |
rs13017637 | 3.906 | 1.084–14.075 | 0.03719 | |
SCN10A | rs12632942 | 0.560 | 0.219–1.430 | 0.225 |
rs6795970 | 1.834 | 0.697–4.826 | 0.2192 | |